Skip to main content

Ibudone and Alcohol/Food Interactions

There are 3 alcohol/food/lifestyle interactions with Ibudone (hydrocodone / ibuprofen).

Major

Hydrocodone Food

Major Food Interaction

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including hydrocodone. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

GENERALLY AVOID: Consumption of alcohol while taking some sustained-release formulations of hydrocodone may cause rapid release of the drug, resulting in high systemic levels of hydrocodone that may be potentially lethal. Alcohol apparently can disrupt the release mechanism of some sustained-release formulations. In study subjects, the rate of absorption of hydrocodone from an extended-release formulation was found to be affected by coadministration with 40% alcohol in the fasted state, as demonstrated by an average 2.4-fold (up to 3.9-fold in one subject) increase in hydrocodone peak plasma concentration and a decrease in the time to peak concentration. Alcohol also increased the extent of absorption by an average of 1.2-fold (up to 1.7-fold in one subject).

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of hydrocodone. The proposed mechanism is inhibition of CYP450 3A4-mediated metabolism of hydrocodone by certain compounds present in grapefruit. Increased hydrocodone concentrations could conceivably increase or prolong adverse drug effects and may cause potentially fatal respiratory depression.

MANAGEMENT: Patients taking sustained-release formulations of hydrocodone should not consume alcohol or use medications that contain alcohol. In general, potent narcotics such as hydrocodone should not be combined with alcohol. Patients should also avoid consumption of grapefruit or grapefruit juice during treatment with hydrocodone.

References

  1. (2013) "Product Information. Zohydro ER (hydrocodone)." Zogenix, Inc
Major

Ibuprofen High Blood Pressure (Hypertension)

Major Potential Hazard, Moderate plausibility

NSAIDs - fluid retention

Fluid retention and edema have been reported in association with the use of nonsteroidal anti-inflammatory drugs (NSAIDs). Therapy with NSAIDs should be administered cautiously in patients with preexisting fluid retention, hypertension, or a history of heart failure. Blood pressure and cardiovascular status should be monitored closely during the initiation of NSAID treatment and throughout the course of therapy.

References

  1. (2002) "Product Information. Motrin (ibuprofen)." Pharmacia and Upjohn
  2. (2002) "Product Information. Nalfon (fenoprofen)." Xspire Pharma
  3. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  4. (2002) "Product Information. Orudis (ketoprofen)." Wyeth-Ayerst Laboratories
  5. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  6. (2006) "Product Information. Anaprox (naproxen)." Roche Laboratories
  7. (2001) "Product Information. Clinoril (sulindac)." Merck & Co., Inc
  8. (2001) "Product Information. Tolectin (tolmetin)." McNeil Pharmaceutical
  9. (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
  10. (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
  11. (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
  12. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  13. (2001) "Product Information. Daypro (oxaprozin)." Searle
  14. (2001) "Product Information. Mobic (meloxicam)." Boehringer-Ingelheim
View all 14 references
Moderate

Ibuprofen High Blood Pressure (Hypertension)

Moderate Potential Hazard, Moderate plausibility

NSAIDs - hypertension

Nonsteroidal anti-inflammatory drugs (NSAIDs), including topicals, can lead to new onset of hypertension or worsening of preexisting hypertension, either of which can contribute to the increased incidence of cardiovascular events. NSAIDs should be used with caution in patients with hypertension. Blood pressure should be monitored closely during the initiation of NSAID therapy and throughout the course of therapy.

References

  1. (2002) "Product Information. Indocin (indomethacin)." Merck & Co., Inc
  2. (2002) "Product Information. Naprosyn (naproxen)." Syntex Laboratories Inc
  3. (2001) "Product Information. Voltaren (diclofenac)." Novartis Pharmaceuticals
  4. (2001) "Product Information. Relafen (nabumetone)." SmithKline Beecham
  5. (2001) "Product Information. Feldene (piroxicam)." Pfizer U.S. Pharmaceuticals
  6. (2001) "Product Information. Dolobid (diflunisal)." Merck & Co., Inc
  7. (2001) "Product Information. Ansaid (flurbiprofen)." Pharmacia and Upjohn
  8. (2001) "Product Information. Lodine (etodolac)." Wyeth-Ayerst Laboratories
  9. (2001) "Product Information. Daypro (oxaprozin)." Searle
  10. (2001) "Product Information. Celebrex (celecoxib)." Searle
  11. (2012) "Product Information. Meclofenamate Sodium (meclofenamate)." Mylan Pharmaceuticals Inc
  12. (2016) "Product Information. Flector Patch (diclofenac topical)." Actavis U.S. (Alpharma USPD)
View all 12 references

Ibudone drug interactions

There are 828 drug interactions with Ibudone (hydrocodone / ibuprofen).

Ibudone disease interactions

There are 29 disease interactions with Ibudone (hydrocodone / ibuprofen) which include:


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.